Achieving effective lipid management in diabetes

Primary Care Cardiovascular Journal

Volumn 2, Issue SUPPL. 1, 2009, Pages

  Kirby, Michael ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET THERAPY; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG POTENTIATION; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; LIMB AMPUTATION; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 77953440808     PISSN: 17565138     EISSN: 17565146     Source Type: Journal    
DOI: 10.3132/pccj.2009.043     Document Type: Article

References (9)

1. JBS2 guidelines. Heart 2005; 91 (Supplement 5):v1-v52; doi:10.1136/hrt.2005.079988
2. National Institute for Health and Clinical Excellence. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2008 (Clinical Guideline 67). www.nice.org.uk/CG67
3. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. 2009 (Clinical Guideline 87). www.nice.org.uk/CG87
4. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. 2008 (Clinical Guideline 66). www.nice.org.uk/CG66
5. National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary hypercholesterolaemia. (Technology Appraisal 132) http://guidance.nice.org.uk/TA132
6. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861
7. Keech AC, Mitchell F, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697
8. Rajamini K, Colman PG, Ping Li L et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788
9. Goff DC Jr, Gerstein HC, Ginsberg HN et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 4i-20i